Ferenci, P; Scherzer, T; Laferl, H; Staufer, K; Maieron, A; Gschwantler, M; Brunner, H; Hubmann, R; Datz, C; Bischof, M; Stauber, R; Kessler, H; Steindl-Munda, P.
High SVR rate, with 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS (R)) plus ribavirin (COPEGUS (R)) in HCV genotype 1 or 4 patients with a week-4 virological response
J CLIN VIROL. 36: S50-S50.
Doi: 10.1016/S1386-6532(06)80153-8
[Oral Communication]
Web of Science
FullText
FullText_MUG